- Home
- TRIN vs ELVN Comparison
TRIN vs ELVN Comparison
Compare TRIN & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRIN
- ELVN
- Stock Information
- Founded
- TRIN 2007
- ELVN 2016
- Country
- TRIN United States
- ELVN United States
- Employees
- TRIN N/A
- ELVN N/A
- Industry
- TRIN Finance/Investors Services
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- TRIN Finance
- ELVN Health Care
- Exchange
- TRIN Nasdaq
- ELVN Nasdaq
- Market Cap
- TRIN 1.1B
- ELVN 1.2B
- IPO Year
- TRIN 2021
- ELVN 2020
- Fundamental
- Price
- TRIN $15.77
- ELVN $19.84
- Analyst Decision
- TRIN Buy
- ELVN Strong Buy
- Analyst Count
- TRIN 4
- ELVN 5
- Target Price
- TRIN $15.75
- ELVN $41.20
- AVG Volume (30 Days)
- TRIN 675.4K
- ELVN 335.0K
- Earning Date
- TRIN 08-06-2025
- ELVN 08-13-2025
- Dividend Yield
- TRIN 12.94%
- ELVN N/A
- EPS Growth
- TRIN 32.58
- ELVN N/A
- EPS
- TRIN 2.25
- ELVN N/A
- Revenue
- TRIN $254,887,000.00
- ELVN N/A
- Revenue This Year
- TRIN $24.11
- ELVN N/A
- Revenue Next Year
- TRIN $4.87
- ELVN N/A
- P/E Ratio
- TRIN $7.02
- ELVN N/A
- Revenue Growth
- TRIN 33.44
- ELVN N/A
- 52 Week Low
- TRIN $12.50
- ELVN $13.30
- 52 Week High
- TRIN $16.82
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- TRIN 63.09
- ELVN 49.97
- Support Level
- TRIN $15.65
- ELVN $19.01
- Resistance Level
- TRIN $16.03
- ELVN $21.01
- Average True Range (ATR)
- TRIN 0.25
- ELVN 1.24
- MACD
- TRIN -0.00
- ELVN 0.15
- Stochastic Oscillator
- TRIN 67.30
- ELVN 60.88
About TRIN Trinity Capital Inc.
Trinity Capital Inc is a closed-end, non-diversified management investment company. The company is engaged in providing debt, including loans and equipment financings, to growth-stage companies, including venture-backed companies and companies with institutional equity investors. Its equipment financings involve loans for general or specific use, including acquiring equipment, secured by the equipment or other assets of the portfolio company.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.